
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is projected to experience robust revenue growth, with a forecasted increase of over 20% annually through 2026, driven by the commercial success of products including Vabysmo, Ojemda, and Miplyffa. The company reported a significant rise in total income from royalty agreements, reaching $28.5 million in 2024, up sharply from $4.8 million in the previous year, suggesting effective management of purchased receivables and customer contracts. Looking forward, XOMA anticipates generating revenues of $49.0 million by 2026, alongside potential contributions from earlier-stage assets and milestone payments, bolstering the company's financial outlook.
Bears say
XOMA Royalty Corp's revenues and net earnings have historically exhibited significant variability, largely attributable to the international market dynamics affecting its operations and services provided to pharmaceutical and biotechnology firms. The company is exposed to potential economic downturns, changes in governmental reimbursement policies, and tariffs, all of which could adversely impact its operational capabilities and market performance. Additionally, factors such as failed clinical trials, the departure of key executives, and the recent removal of a near-term revenue driver from the profit and loss statement contribute to a challenging outlook for XOMA's stock.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares